rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Current Antipsychotics
  name:
    name part: Gross, Gerhard.
    role:
      role term: editor.
  name:
    name part: Geyer, Mark A.
    role:
      role term: editor.
  name:
    name part: SpringerLink (Online service)
  type of resource: text
  origin info:
    place:
      place term: gw
    date issued: 2012
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: electronic
    form: electronic resource
    reformatting quality: access
    form: remote
    extent: X, 418 p. online resource.
  abstract: Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to…
  table of contents: Preface -- Dopaminergic dysfunction in psychotic disorders.- Role of dopamine D2 receptors for antipsychotic activity -- Dopamine receptor signaling pathways and antipsychotics -- Serotonergic mechanisms as targets for existing and novel antipsychotics -- Antipsychotics in the treatment of psychoses during development -- Weight gain and metabolic disturbances induced by antipsychotic treatments -- Medical needs in the treatment of psychotic disorders -- Antipsychotics in the treatment of bipolar disorders -- Pharmacogenomics of antipsychotics -- Drug interactions and drug monitoting of antipsychotics -- Delivery systems and dosing for antipsychotics -- Imaging as tool to investigate psychoses and antipsychotics -- Biomarkers for antipsychotic therapies -- Behavioral animal models of antipsychotic drug actions. .
  note: edited by Gerhard Gross, Mark A. Geyer.
  subject:
    topic: Medicine
  subject:
    topic: Pharmacy
  subject:
    topic: Neurosciences
  subject:
    topic: Pharmacology
  subject:
    topic: Behavioral sciences
  subject:
    topic: Proteins
  subject:
    topic: Neurobiology
  subject:
    topic: Biomedicine
  subject:
    topic: Pharmacology/Toxicology
  subject:
    topic: Neurosciences
  subject:
    topic: Receptors
  subject:
    topic: Neurobiology
  subject:
    topic: Behavioral Sciences
  subject:
    topic: Pharmacy
  classification: RM1-950
  classification: 615
  related item:
    title info:
      title: Springer eBooks
  related item:
    title info:
      title: Handbook of Experimental Pharmacology, 212
  identifier: 9783642257612
  identifier: http://dx.doi.org/10.1007/978-3-642-25761-2
  record info:
    record creation date: 121116
    record change date: 20151204154745.0
    record identifier: 978-3-642-25761-2